Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Other Non Operating Income (2016 - 2026)

Akebia Therapeutics has reported Other Non Operating Income over the past 10 years, most recently at -$175000.0 for Q4 2025.

  • Quarterly Other Non Operating Income fell 418.18% to -$175000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$213000.0 through Dec 2025, down 260.15% year-over-year, with the annual reading at $94000.0 for FY2024, N/A changed from the prior year.
  • Other Non Operating Income was -$175000.0 for Q4 2025 at Akebia Therapeutics, down from -$10000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $1.3 million in Q2 2021 and troughed at -$906000.0 in Q3 2022.
  • The 5-year median for Other Non Operating Income is -$10000.0 (2023), against an average of $132333.3.
  • Year-over-year, Other Non Operating Income skyrocketed 604.35% in 2022 and then crashed 418.18% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $1.3 million in 2021, then tumbled by 171.62% to -$906000.0 in 2022, then surged by 74.72% to -$229000.0 in 2023, then surged by 124.02% to $55000.0 in 2024, then crashed by 418.18% to -$175000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Non Operating Income are -$175000.0 (Q4 2025), -$10000.0 (Q3 2025), and -$28000.0 (Q2 2025).